Guru Sonpavde, GU Oncology and Phase I Clinical Trials Director, Chair of Bladder Cancer Research at AdventHealth Central Florida, Professor of Medicine at the University of Central Florida, and at Loma Linda University Health, shared a post on LinkedIn:
“GU 2026 bladder cancer presentation: Promising activity and feasibility of combination pan-FGFR inhibitor Erdafitinib + EV (enfortumab vedotin) for advanced urothelial carcinoma – ORR of 93.3% (14 of 15 patients) post platinum-based chemotherapy and PD1/L1 inhibitor therapy, suggesting synergism.
Pleased to mentor Rohit Jain and develop this combination with support from the Experimental Therapeutics Clinical Trials Network (ETCTN) National Cancer Institute (NCI), the feasibility and activity of the combination of EV-pembro + Vepugratinib, a more specific FGFR3 inhibitor, as first-line therapy is ongoing.”
Other articles about FGFR on OncoDaily.